Sep 23, 2021Verve Therapeutics Reports New Preclinical Data with VERVE-101 Demonstrating Robust, Durable and Precise Editing of the PCSK9 Gene for the Treatment of Cardiovascular Disease
Sep 23, 2021Verve Therapeutics Announces Development of Proprietary GalNAc-LNP Delivery Technology Enabling Efficient In Vivo Liver Delivery of Base Editors
Aug 12, 2021Verve Therapeutics Announces Business and Program Highlights and Reports Second Quarter 2021 Financial Results
Jun 21, 2021Verve Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Jun 01, 2021Verve Therapeutics Appoints Leading Biotechnology Executive Michael MacLean to its Board of Directors
May 19, 2021Verve Therapeutics Announces Nature Publication Highlighting its Use of Base Editing to Potently and Durably Lower Blood PCSK9 and LDL-C in Non-Human Primates
May 11, 2021Verve Therapeutics to Present Preclinical Data from Gene Editing Programs for the Treatment of Atherosclerotic Cardiovascular Disease at ASGCT
